Compare Novavax Inc (NVAX) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Paychex, Inc. — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Paychex, Inc. trades at $103.98 (market cap $37.19B). The key difference: Paychex, Inc. is far larger — about 20.4× Novavax Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Paychex, Inc. for 56 Days on average.
| NVAX | PAYX | |
|---|---|---|
Market Cap | $1.82B | $37.19B |
Volume | 6,198,505 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $12.56 | $128.59 |
52-Week Low | $6.22 | $85.57 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $1.39B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Paychex (PAYX) trades at $103.98, up 2.39% with a bullish technical signal despite mixed indicators. The company demonstrates strong fundamentals with consistent earnings beats, 27.35% net margins, and robust profitability metrics. Recent news highlights investor concerns about dividend sustainability despite solid Q1 2027 results showing 6% revenue growth and double-digit earnings increases driven by PEO and insurance segments.
Outlook remains cautiously optimistic with a $111 consensus price target offering 6.8% upside. Key risks include labor market sensitivity and competitive pressures, while opportunities lie in AI integration and PEO growth. The stock presents a balanced risk-reward profile with dividend stability supporting investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
